Weiguo Chen
Impact in
- Cancer Research top 2%
- Breast Cancer Treatment Studies
- MicroRNA in disease regulation
- Health Informatics top 5%
Papers in
-
- Breast Cancer Treatment Studies 52
- Oncology 59
- HER2/EGFR in Cancer Research 31
- Cancer Risks and Factors 10
Weiguo Chen
151 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 142
- Cancer Research 734
- Health Informatics 40
- Oncology 604
- Radiology, Nuclear Medicine and Imaging 436
- Pathology and Forensic Medicine 252
Countries citing papers authored by Weiguo Chen
This map shows the geographic impact of Weiguo Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiguo Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiguo Chen more than expected).
Fields of papers citing papers by Weiguo Chen
This network shows the impact of papers produced by Weiguo Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiguo Chen. The network helps show where Weiguo Chen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Weiguo Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 0 | |
| 9 | 2022 | 11 | |
| 10 | 2022 | 18 | |
| 11 | 2022 | 41 | |
| 12 | 2021 | 34 | |
| 13 | 2021 | 1 | |
| 14 | 2020 | 7 | |
| 15 | [Risk factors of non-sentinel lymph node metastasis and performance of MSKCC nomogramin breast cancer patients with metastatic sentinel lymph node]. | 2015 | 6 |
| 16 | 2015 | 26 | |
| 17 | Imaging Diagnosis of Aggressive Osteoblastoma | 2011 | 2 |
| 18 | Fox-2 Splicing Factor Binds to a Conserved Intron Motif to Promote Inclusion of Protein \n4.1R Alternative Exon 16 | 2006 | 94 |
| 19 | 2005 | 3 | |
| 20 | 2004 | 53 |
About Weiguo Chen
Weiguo Chen is a scholar working on Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 168 papers that have together received 2.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (52 papers), HER2/EGFR in Cancer Research (31 papers), AI in cancer detection (25 papers), Breast Lesions and Carcinomas (22 papers), Digital Radiography and Breast Imaging (20 papers), Radiomics and Machine Learning in Medical Imaging (20 papers), Advanced Breast Cancer Therapies (13 papers) and Cancer Risks and Factors (10 papers). The work is most often cited by research in Cancer Research (734 citations), Health Informatics (40 citations), Oncology (604 citations), Radiology, Nuclear Medicine and Imaging (436 citations) and Pathology and Forensic Medicine (252 citations). Weiguo Chen has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Kunwei Shen, Jiayi Wu, Xiaosong Chen, Yafen Li, Ou Huang, Li Zhu, Jianrong He, Genggeng Qin, Xiaochun Fei and Hui Zeng. Their work appears in journals such as Frontiers in Oncology, BMC Cancer, Oncotarget, Medical Physics and European Radiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.